1. Home
  2. XOMA vs PROC Comparison

XOMA vs PROC Comparison

Compare XOMA & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMA
  • PROC
  • Stock Information
  • Founded
  • XOMA N/A
  • PROC 1976
  • Country
  • XOMA United States
  • PROC Luxembourg
  • Employees
  • XOMA N/A
  • PROC N/A
  • Industry
  • XOMA Biotechnology: Pharmaceutical Preparations
  • PROC Biotechnology: Pharmaceutical Preparations
  • Sector
  • XOMA Health Care
  • PROC Health Care
  • Exchange
  • XOMA Nasdaq
  • PROC Nasdaq
  • Market Cap
  • XOMA 298.3M
  • PROC 283.2M
  • IPO Year
  • XOMA N/A
  • PROC N/A
  • Fundamental
  • Price
  • XOMA $28.59
  • PROC $2.40
  • Analyst Decision
  • XOMA Strong Buy
  • PROC Hold
  • Analyst Count
  • XOMA 2
  • PROC 1
  • Target Price
  • XOMA $57.00
  • PROC $4.50
  • AVG Volume (30 Days)
  • XOMA 32.2K
  • PROC 3.6K
  • Earning Date
  • XOMA 08-06-2024
  • PROC 09-03-2024
  • Dividend Yield
  • XOMA N/A
  • PROC N/A
  • EPS Growth
  • XOMA N/A
  • PROC N/A
  • EPS
  • XOMA N/A
  • PROC 0.52
  • Revenue
  • XOMA $5,811,000.00
  • PROC $414,096,000.00
  • Revenue This Year
  • XOMA $349.94
  • PROC $5.54
  • Revenue Next Year
  • XOMA $28.50
  • PROC $8.54
  • P/E Ratio
  • XOMA N/A
  • PROC $4.62
  • Revenue Growth
  • XOMA 73.10
  • PROC N/A
  • 52 Week Low
  • XOMA $13.48
  • PROC $1.95
  • 52 Week High
  • XOMA $29.00
  • PROC $4.95
  • Technical
  • Relative Strength Index (RSI)
  • XOMA 61.84
  • PROC 37.76
  • Support Level
  • XOMA $25.46
  • PROC $2.49
  • Resistance Level
  • XOMA $27.05
  • PROC $2.81
  • Average True Range (ATR)
  • XOMA 1.27
  • PROC 0.09
  • MACD
  • XOMA 0.34
  • PROC -0.01
  • Stochastic Oscillator
  • XOMA 92.36
  • PROC 0.00

About XOMA XOMA Corporation

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

About PROC Procaps Group S.A.

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Share on Social Networks: